Pfizer secured the FDA's approval of BOSULIF (bosutinib) on September 26, a regulatory win expected to bolster the pharmaceutical giant's oncology revenue streams and expand its market penetration in the targeted therapy sector.
Pfizer secured the FDA's approval of BOSULIF (bosutinib) on September 26, a regulatory win expected to bolster the pharmaceutical giant's oncology revenue streams and expand its market penetration in the targeted therapy sector.